Peptide directory

CJC-1295 DAC is a modified GHRH(1-29) analog engineered with a Drug Affinity Complex that covalently binds serum albumin after injection, extending its half-life to roughly 6–8 days. The retrieved literature includes randomized placebo-controlled ascending-dose trials in healthy humans showing sustained GH and IGF-1 elevation with preserved pulsatility.

GHRP-2 is a synthetic growth hormone secretagogue and ghrelin receptor agonist. The retrieved literature treats it primarily as a tool for studying GH secretion, appetite regulation, and growth physiology rather than as an established therapeutic drug.

GHRP-6 is a synthetic GH secretagogue hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, MW 872.44 Da). In humans it is concentrated in endocrine challenge tests, diagnostic protocols, and mechanistic studies — particularly as part of the GHRH/GHRP-6 test for adult GH deficiency — rather than in therapeutic outcome trials.

Hexarelin is a potent synthetic growth-hormone secretagogue. Relative to ipamorelin it is less selective: it reliably stimulates GH but also stimulates prolactin, ACTH, and cortisol, giving it a stronger pharmacodynamic footprint and a rougher endocrine side-effect profile.

"Human growth hormone" in modern therapeutics refers to recombinant somatropin. Approved somatropin products such as Omnitrope cover pediatric growth hormone deficiency, Prader–Willi syndrome, small-for-gestational-age children, Turner syndrome, idiopathic short stature, and adult growth hormone deficiency. It is one of the most well-characterized peptide hormone therapies in modern endocrinology.

IGF-1 LR3 is a synthetic 83-amino-acid analog of IGF-1 with an arginine substitution at position 3 plus a 13-amino-acid N-terminal extension. It is predominantly a research reagent; the retrieved literature did not identify a substantial clinical efficacy program in humans specific to LR3.

Ipamorelin is a synthetic pentapeptide developed as a selective growth-hormone secretagogue. Its main pharmacologic attraction relative to hexarelin is selectivity: it stimulates GH cleanly and, in profiling work, does not materially raise ACTH or cortisol.

Mod GRF 1-29 is commonly treated as the same molecule as CJC-1295 without DAC — a short-acting, stabilized analog of the active N-terminal portion of GHRH. Peer-reviewed analytical literature identifies the molecule as (D-Ala2, Gln8, Ala15, Leu27)-GRF amide, distinguishing it from longer-acting DAC-containing forms.

Sermorelin is a synthetic analog of the first 29 amino acids of human growth hormone-releasing hormone (GHRH(1-29)NH2). It was FDA-approved as Geref for both GH-reserve diagnostic testing and pediatric growth hormone deficiency treatment; the FDA documented that the products were later withdrawn from sale, but not for reasons of safety or effectiveness.

Tesamorelin is a synthetic growth hormone-releasing factor analog, FDA-approved as Egrifta SV and Egrifta WR formulations for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The two formulations are explicitly not substitutable. It is not a general weight-loss drug.